Summary of Key Points Core Viewpoint The Beijing Stock Exchange (BSE) has seen a decrease in trading volume and value over the past week, with a total of 287 listed companies as of December 21, 2025. The market is also witnessing new listings and applications for IPOs, indicating ongoing activity despite the recent declines in trading metrics. Trading Metrics - As of December 21, 2025, the BSE has 287 listed companies with a total share capital of 39.676 billion shares and a circulating share capital of 25.312 billion shares [2] - For the week of December 22-27, 2025, the trading volume was 4.634 billion shares, a decrease of 6.63% week-over-week [3] - The trading value for the same week was 99.934 billion yuan, down 11.68% from the previous week [3] - The average trading price was 21.57 yuan, reflecting a decrease of 5.41% [3] - The BSE 50 Index fell by 1.19% to 1463.04 points, with 28 stocks rising and 22 falling [3] New Listings and IPO Applications - During the week of December 22-27, 2025, one company was listed, and one company opened for subscription [6][12] - A total of 9 companies had their IPO applications accepted, while 4 companies passed the review process [6][38] - As of December 27, 2025, there are 160 companies awaiting review, with 13 accepted, 121 under inquiry, and 14 submitted for registration [6] Recent IPOs - Jiangtian Technology (江天科技) was listed on December 25, 2025, becoming the 287th company on the BSE, with a first-day closing price of 47.85 yuan, up 180.58% from its issue price [8][9] - The company aims to raise 531 million yuan for the construction of a comprehensive R&D and manufacturing base [9] - For the first three quarters of 2025, Jiangtian Technology reported a revenue of 468 million yuan, a year-on-year increase of 10.85%, and a net profit of 89.11 million yuan, up 11.45% [11] Upcoming IPOs - Hengtong Optoelectronics (蘅东光) opened for subscription on December 23, 2025, with a target of raising 323.8 million yuan [13] - The company reported a revenue of 1.315 billion yuan for 2024, a significant increase of 91.38% year-on-year, and a net profit of 224 million yuan, up 123.75% [16] - Other companies, including Miro Technology (觅容科技) and Meiya Technology (美亚科技), have submitted registration applications, aiming to raise 314 million yuan and 200 million yuan, respectively [19][22] Companies Passing Review - Four companies passed the listing committee review during the week, including Ying's Holdings (英氏控股) and Longyuan Co., Ltd. (隆源股份) [24][26] - Ying's Holdings reported revenues of 1.974 billion yuan for 2024, with a net profit of 210 million yuan [25] - Longyuan Co., Ltd. aims to raise 560 million yuan for projects related to new energy systems [28] Companies Completing Counseling - A total of 28 companies completed their counseling work during the week [68] - These companies are preparing for their IPOs, indicating a robust pipeline for future listings on the BSE [68]

Core Viewpoint - Puang Medical is advancing its listing process on the Beijing Stock Exchange, having received the first round of review inquiries, with plans to raise approximately 395 million yuan for various projects, including smart manufacturing and R&D in minimally invasive medical devices [1] Group 1: Company Overview - Established in 2013, Puang Medical specializes in the R&D, production, and sales of medical devices for diabetes care, general drug infusion, and minimally invasive interventions, targeting chronic disease treatments [1][2] - The company has been recognized as a national-level "specialized and innovative" small giant enterprise and has received multiple awards for its technological innovations [2] Group 2: Product and Market Position - The main products include diabetes care devices, general drug infusion devices, and minimally invasive intervention devices, with a focus on safety, minimally invasive procedures, and patient comfort [2][3] - The insulin pen needle is the company's core product, accounting for 65.80% of its main business revenue in 2024, and the company is a key player in both domestic and international markets [3][4] Group 3: Industry Trends and Future Outlook - The puncture intervention industry is characterized by high technical barriers and complex production processes, with a trend towards high-end, intelligent, safe, minimally invasive, and painless solutions [3][6] - With the issuance of the first review inquiry letter, the company is at a critical stage in its listing process, which, if successful, will enhance its production capabilities and R&D levels in the puncture intervention field [5][6]